newsfilter
← Latest News
GlobeNewswire·

Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will